Human Anti-CTLA-4 Antibody in Combination with a gp100 Melanoma Vaccine Shows Significant Benefit in Treating Metastatic Melanoma
Apr 25, 2005, 08:06, Reviewed by: Dr.
|
|
"We are encouraged by the duration of responses in this metastatic melanoma patient population and look forward to the results of the Phase III clinical trial and other trials that investigate the ability of MDX-010 to offer a new approach to treating cancer."
|
By Medarex, Inc. and Bristol-Myers Squibb Company ,
Medarex, Inc. ( Nasdaq: MEDX ) and Bristol-Myers Squibb Company ( NYSE: BMY ) announced today that complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over 34 months, with five of the seven responses ongoing for more than two years.
These patients were treated in a Phase II clinical study with the investigational fully human anti-CTLA-4 antibody, MDX-010, in combination with MDX-1379, a gp100 melanoma vaccine. The Phase II clinical trial was conducted by Steven A. Rosenberg, M.D., Ph.D., chief of Surgery at the National Cancer Institute, under a Cooperative Research and Development Agreement with Medarex. Results from the clinical trial were presented at the 96th Annual Meeting of the American Association of Cancer Research, April 16-20, 2005, in Anaheim, California.
The Phase II clinical trial evaluated two dose regimens of MDX-010 in combination with MDX-1379 in a total of 56 patients with metastatic melanoma. All patients had stage IV disease, Karnofsky performance status greater than or equal to 60, no previous MDX-010 treatment or gp100 vaccination, no evidence of autoimmune or immunodeficiency, and three weeks had elapsed since any previous systemic cancer therapy. Of the 56 patients, 29 patients ( cohort 1 ) received 3.0 mg/kg intravenously over 90 minutes of MDX-010 and MDX-1379 every three weeks, and 27 patients ( cohort 2 ) received an initial dose of 3.0 mg/kg intravenously over 90 minutes of MDX-010 and MDX-1379, followed by subsequent doses of 1.0 mg/kg of MDX-010 every three weeks.
Data on the initial 14 patients in cohort 1 and the initial 24 patients in cohort 2 were previously presented at the 2003 annual meeting of the American Society of Clinical Oncology.
Four of the 29 patients treated in cohort 1 experienced complete or partial responses. Two patients experienced complete responses that are ongoing at over 30 and 31 months, respectively, and two additional patients experienced partial responses, with one response lasting four months and the other ongoing at over 34 months. In cohort 2, three of 27 patients experienced partial responses, with one partial response ongoing to six months and two partial responses ongoing at 25 and 26 months, respectively.
Grade III/IV adverse events were reported in nine of 29 patients in cohort 1 and five of 27 patients in cohort 2, with colitis ( seven patients ) and dermatitis ( four patients ) being the most frequently reported.
All of the Grade III/IV events were normalized or managed with medical treatment involving hospitalization, intravenous hydration, steroids, or other medical management. The management of immune-mediated toxicities required strict attention to patient complaints and prompt diagnosis, as they could require surgery or potentially be lethal if not vigorously treated. Of the seven patients who experienced complete or partial responses in the Phase II clinical trial, Grade III/IV events were reported in all five patients with ongoing duration of response greater than or equal to 25 months; no Grade III/IV events were reported in the two patients who experienced partial responses of four and six months duration.
"We are encouraged by the duration of responses in this metastatic melanoma patient population and look forward to the results of the Phase III clinical trial and other trials that investigate the ability of MDX-010 to offer a new approach to treating cancer," said Donald L. Drakeman, president & CEO of Medarex.
About MDX-010
MDX-010 is a fully human antibody against human CTLA-4, a molecule on T cells that is believed to be responsible for suppressing the immune response.
MDX-010 is in clinical studies to investigate its potential to enable the immune systems of cancer patients to fight tumors. MDX-010 is currently in a Phase III clinical trial for metastatic melanoma and in multiple Phase II clinical trials to investigate the product's potential activity in other tumor types.
The potential use of MDX-010 outside oncology is also being explored. Further information regarding Medarex's and Bristol-Myers Squibb's MDX-010 program can be found in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission ( SEC ). 
- Results from the clinical trial were presented at the 96th Annual Meeting of the American Association of Cancer Research, April 16-20, 2005, in Anaheim, California.
www.medarex.com
Further information regarding Medarex's and Bristol-Myers Squibb's MDX-010 program can be found in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission ( SEC ).
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery and development of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb� technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Twenty-two of these therapeutic products derived from Medarex technology are currently in human clinical testing, with the most advanced product presently in a Phase III clinical trial. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
For more information, contact: Bristol-Myers Squibb - Kathy Baum, Business and R&D Communications, 609-252-4227, or John Elicker, Investor Relations, -212-546-3775; Medarex - Laura S. Choi, Investor Relations, 609-430-2880, ext. 2216, or Jean Mantuano, Corporate Communications ( media ), 609-430-2880, ext. 2221
For Bristol-Myers Squibb: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Among other risks, there can be no guarantee that MDX-010 will be submitted for regulatory approval, will receive regulatory approval, or, if approved, will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2004 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For Medarex: Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of MDX-010 and/or MDX-1379 in patients, uncertainties related to product manufacturing as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission ( SEC ), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2004 and any subsequent Quarterly Reports on Form 10-Q. There can be no assurance that such development efforts will succeed, that MDX-010 or other developed products will receive required regulatory approval or that, even if such regulatory approval were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.
Medarex�, the Medarex logo and UltiMAb� are registered trademarks of Medarex, Inc. All rights are reserved.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
